A failed drug can still move a program forward, which is the unusual position Sionna Therapeutics is in heading into the 2026 North American Cystic Fibrosis Conference. Post hoc analyses from the PreciSION CF Phase 2a trial of SION-719, a study that missed its key sweat chloride endpoint, with a mean placebo-adjusted change of only -1.0 mmol/L, are now being cited to justify advancing a different compound pair into the next trial.
That next trial is AscenSION CF, a Phase 2a proof-of-concept study that will combine SION-451, an NBD1 stabilizer targeting the conformational instability caused by the F508del mutation, with SION-2222 (galicaftor), a TMD1-directed CFTR corrector. The pairing reflects Sionna’s core hypothesis: that simultaneously stabilizing NBD1 and correcting TMD1 could produce fuller CFTR correction than any single mechanism alone. The conference presentation is the first public airing of the PreciSION post hoc data that, in the company’s read, supports this two-drug design.
The strategic logic here is worth watching carefully. Sionna is essentially arguing that SION-719’s trial taught them something specific about which patients and which CFTR domains respond to modulation, and that those signals, extracted after the primary endpoint failed, point toward the SION-451 plus SION-2222 combination. Post hoc subgroup analyses are common in CF development, and regulators accept them as hypothesis-generators rather than confirmatory evidence. The real test is whether AscenSION CF produces a primary endpoint result. Trikafta already dominates CFTR modulation for F508del patients, so any new regimen will face a high efficacy bar just to show differentiation, let alone to demonstrate superiority or meaningful additive benefit.
The conference presentation on October 9 is not a data readout in its own right; it is Sionna making its scientific case publicly before AscenSION CF generates its own numbers. The detail to watch when those data emerge is sweat chloride reduction in F508del-homozygous patients already on background therapy, because that is the domain where PreciSION CF fell short and where the post hoc analyses are now being asked to do predictive work.
SION-451: the facts in one place
- Also written: SION 451, SION451
- Sponsor: Sionna Therapeutics, Inc.
- Mechanism: nucleotide-binding domain 1 (NBD1) stabilizer; directly stabilizes CFTR NBD1
- Indication studied: cystic fibrosis
- Phase: Phase 1 completed; Phase 2a planned
- Enrollment: 120
- Primary endpoint: safety, tolerability, and pharmacokinetics
- Headline result: generally well-tolerated and met target pharmacokinetic exposures; SION-451 + SION-2222 selected as preferred dual combination
- Registry identifier: NCT07035990
- Current status: Phase 1 completed; Phase 2a proof-of-concept trial (AscenSION CF) planned to initiate Q1 2027; under FDA review
- Phase 1 initiation announced: August 13, 2024
- First subjects dosed in Phase 1 dual combination trial: August 25, 2025
- Topline Phase 1 data reported: August 10, 2026
- Plans to advance to Phase 2a announced: September 14, 2026
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
